Valuation
- Market cap
- 5,672,000
- Revenue TTM
- $0
- Net income TTM
- $-4,280,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 7,500
- Avg volume
- 13,674
- Day's range
- $0.03 – $0.04
- Shares out
- 94,540,000
- Stochastic %K
- 25%
- Beta
- -9.41
- Analysts
- Strong Buy
- Price target
- —
Company profile
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert, a simple, cost-effective test for determining smoking stat...
Show more
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert, a simple, cost-effective test for determining smoking status; and TobacAlert, a test for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment and prevention of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 800 936 9669
- Website
- https://nymox.com
- Address
- Bay & Deveaux Streets, 2nd Floor, Nassau, Bahamas
Latest news
No headlines yet.
